Acceder
¡Bienvenido a Rankia España! Volver a Rankia Argentina

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
15.801 / 17.024
#126401

Re: Farmas USA


@franco-vega

lo de ayer de TEVA que fue? hubo news?

semanal tempranero .... iHCH completado, espero pullback para consolidar y veremos si breakout de la MM50 semanal en unos dias ... de ser asi, veriamos los 13's de nuevo.
Iremos viendo dia a dia 

Si cuando digo que arrieritos somos ... y en el camino nos encontraremos. La tengo en la mira ... esta me devuelve lo poco que me quito ...

#126402

Re: Farmas USA

IB - D6

En principio , por lo que me han comentado y porque en el informe de actividad del día de ayer todavía me sigue saliendo UK. El proceso de traspaso aún no se ha realizado por lo que.....a efectos D6 la ubicación (tengo dudas entre UK o USA) debería ser la puesta el año pasado.

#126405

Re: Farmas USA

OFF, please.
IB
Sigo teniendo el mismo número de cuenta. He estado mirando y no veo ningún sitio donde ponga UK.
¿Dónde te aparece? Lo has dicho, pero, para torpes. En el correo que mandan a diario para decir que ya tienes el informe no aparece. Que no lo veo.
Supuestamente hice la migración.
Ya estamos con hostias.
Edito:
Lo veo. UK. Su muelas,,,

Si te sientas en la mesa y no descubres al "primo" es que lo eres tú.

#126406

Re: Farmas USA

IB

Perdona, veo ahora tu mensaje. A ver si hacen de una maldita vez la migración y nos asentamos en Irlanda. (Por cierto me consta que ha habido gente que han pasado a Hungría o Luxemburgo). 
#126407

Re: Farmas USA

KpTI

Su partner Antengene presenta solicitud de nuevo fármaco en China

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) announced that it submitted an Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) for ATG-010 (selinexor) in the treatment of Endometrial Cancer. This is a global Phase 3, multicenter, randomized, double-blind trial (SIENDO) aiming to evaluate the efficacy of ATG-010 compared to placebo as maintenance therapy in patients with advanced or recurrent endometrial cancer after combination chemotherapy and is being conducted at approximately 80 investigative sites around the world, including North America, Europe and Asia.   Endometrial cancer is the most common cancer of the female reproductive tract and for patients who progress following initial chemotherapy there are limited treatment options with poor prognosis. The highest incidence rates are reported in developed countries and some economically developed areas of China. In recent years, with an increase in the prevalence of obesity, diabetes and hypertension, the incidence and mortality rate of endometrial cancer has been increasing with a trend towards younger women.   ATG-010 is a first-in-class and only-in-class oral selective inhibitor of nuclear export, developed by Antengene and Karyopharm Therapeutics Inc. (NASDAQ:KPTI). It has been approved by the US Food and Drug Administration (FDA) for use in both multiple myeloma and diffuse large B-cell lymphoma, which are two major indications in hematological malignancies. In addition, the Phase 3 SIENDO trial of ATG-010 in patients with endometrial cancer has passed the planned interim futility analysis and the Data and Safety Monitoring Board (DSMB) recommended the trial should proceed as planned without any modification.   "The positive data of the Phase 3 SEAL trial in liposarcoma and the ongoing Phase 3 SIENDO trial in endometrial cancer which just passed the interim analysis have suggested substantial potential of ATG-010 across multiple solid tumors. Filing an IND with the NMPA in China is an important step in the clinical development of ATG-010 as we expect to explore additional therapeutic areas of our novel oral drug candidate," said Dr. Jay Mei, Founder, Chairman and CEO of Antengene. "We look forward to initiating the Phase 3 global trial in patients with advanced or recurrent endometrial cancer in China, to provide Chinese patients with better treatment options."   Professor Qi Zhou from the Gynecological Oncology Center of Chongqing University Cancer Hospital, the leading clinical investigator, said: "R&D capability in China has improved significantly in recent years. There are more innovative anti-tumor drugs moving towards clinical research and commercialization, and they are widely used in clinical practice. The emergence of targeted and immunotherapy drugs effectively improved the prognosis of patients. I look forward to advancing the research of ATG-010, a first-in-class selective nuclear export inhibitor, with Antengene, to improve the effect and increase the accessibility of treatment, so that patients can benefit from clinical results as soon as possible." .

«Después de nada, o después de todo/ supe que todo no era más que nada.»